This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (39) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hirose, T. Articles by Nabeshima, T. Search for Related Content PubMed PubMed Citation Articles by Hirose, T. Articles by Nabeshima, T. Social Bookmarking                         What's this?

Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile

Second Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japant_hirose{at}research.otsuka.co.jp

Yasufumi Uwahodo

Second Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan

Sakiko Yamada

Aripiprazole Project, Product Planning and Management Group, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan

Takashi Miwa

Tetsuro Kikuchi

Hisashi Kitagawa

Second Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan

Kevin D. Burris

Palatin Technologies, Cranbury, NJ, USA

C. Anthony Altar

Psychiatric Genomics, Inc., Gaithersburg, MD, USA

Toshitaka Nabeshima

Nagoya University Graduate School of Medicine, Department of Neuropsychopharmacology and Hospital Pharmacy, Japan

The antipsychotic efficacy of aripiprazole is not generally associated with extrapyramidal symptoms, cardiovascular effects, sedation or elevations in serum prolactin that characterize typical or atypical antipsychotics. The aim of this study was to clarify the mechanism of action of aripiprazole that underlies its favourable clinical profiles. The preclinical efficacy and side-effect profiles of aripiprazole were evaluated usingseveral pharmaco-behavioural test systems in mice and rats, both in vivo and ex vivo, and compared with those of other conventional and atypical antipsychotics. Each of the antipsychotics induced catalepsy and inhibited apomorphine-induced stereotypy. The catalepsy liability ratios for these drugs were 6.5 for aripiprazole, 4.7 for both olanzapine and risperidone. The ptosis liability ratios for aripiprazole, olanzapine and risperidone were 14, 7.2 and 3.3, respectively. Aripiprazole slightly increased DOPA accumulation in the forebrain of reserpinised mice, reduced 5-HTP accumulation at the highest dose and exhibited a weaker inhibition of 5-methoxy-N,N-dimethyl-tryptamine-induced head twitches. Aripiprazole did not inhibit physostigmine- or norepinephrine-induced lethality in rats. In conclusion, aripiprazole shows a favourable preclinical efficacy and side-effect profile compared to a typical antipsychotics. This profile may result from its high affinity partialagonist activity at D₂ and 5-HT_1A receptors and its antagonism of 5-HT_2A receptors.

Key Words: aripiprazole • efficacy • olanzapine • risperidone • side-effects

Journal of Psychopharmacology, Vol. 18, No. 3, 375-383 (2004)
DOI: 10.1177/026988110401800308


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. H. Young, D. A. Oren, A. Lowy, R. D. McQuade, R. N. Marcus, W. H. Carson, N. H. Spiller, A. F. Torbeyns, and R. Sanchez Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study The British Journal of Psychiatry, January 1, 2009; 194(1): 40 - 48. [Abstract] [Full Text] [PDF]

				N. Dimopoulos, C. Mitsonis, and V. Psarra Delusional disorder, somatic type treated with aripiprazole--mirtazapine combination J Psychopharmacol, September 1, 2008; 22(7): 812 - 814. [Abstract] [PDF]

				A. Salmoiraghi and M. Odiyoor A case of Aripiprazole and extra pyramidal side effects J Psychopharmacol, July 1, 2006; 20(4): 592 - 593. [Abstract] [PDF]

				M. K. Nickel, M. Muehlbacher, C. Nickel, C. Kettler, F. P. Gil, E. Bachler, W. Buschmann, N. Rother, R. Fartacek, C. Egger, et al. Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Placebo-Controlled Study Am J Psychiatry, May 1, 2006; 163(5): 833 - 838. [Abstract] [Full Text] [PDF]

				S. Karim and E. J. Byrne Treatment of psychosis in elderly people Adv. Psychiatr. Treat., July 1, 2005; 11(4): 286 - 296. [Abstract] [Full Text] [PDF]